|
Braveheart Investment Group PLC - Dodworth, England-based investment company - Updates on Kirkstall Ltd, a company within its investment portfolio. Says Kirkstall, in conjunction with the Biomedical Ultrasonics, Biotherapy & Biopharmaceutical Laboratory within the Institute of Biomedical Engineering at the University of Oxford, has developed an ‘organ on a chip’ model of a milli-fluidic system, human blood-brain barrier which has been used to map the interaction between the blood-brain barrier and brain cancer. Explains this is the first time a dynamic milli-fluidic model has been developed where the interactions between the blood-brain barrier and medulloblastoma brain cancer spheroids have been demonstrated. Braveheart holds an 86% equity interest in Kirkstall. Current stock price: 12.19 pence, down 0.5% in London on Friday 12-month change: up 16% Copyright 2023 Alliance News Ltd. All Rights Reserved.
|
